Search

Displaying results 2001 - 2010 of 5895 in total
  1. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_. … As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists

    Products: ESOMEPRAZOLO GENERICS, ESOMEPRAZOLO DOC GENERICI
  2. Drug

    Iopromide

    go.drugbank.com/drugs/DB09156
    Approved

    [A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. … iopromide can cause several serious adverse effects, including cardiac events, thromboembolism, hypersensitivity reaction, and even death if administered intrathecally inadvertently, it is still deemed to

  3. Drug

    Lamotrigine

    go.drugbank.com/drugs/DB00555
    ApprovedInvestigational

    Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Dru...

  4. Drug

    Trimipramine

    go.drugbank.com/drugs/DB00726
    ApprovedInvestigational

    Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. … [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase

  7. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity.

  8. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  9. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  10. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet … As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically

    Synonyms: allopregnan-3α-ol-20-one